Artivion, Inc. Stock Price, News & Analysis

Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery, announced its participation in the Oppenheimer 33rd Annual Healthcare Conference. The virtual event is set for March 14, 2023, at 3:20 p.m. ET. A live webcast will be available on Artivion's website, with a 90-day archive post-event. Headquartered in Atlanta, Georgia, Artivion specializes in solutions for aortic disease, offering products like aortic stents, surgical sealants, and On-X mechanical heart valves. The company operates in over 100 countries globally. For more information, visit www.artivion.com.

Artivion, Inc. (NYSE: AORT) reported its fourth quarter and full-year 2022 results. The fourth quarter revenues were $79.4 million, flat year-over-year, but up 5% on a non-GAAP constant currency basis. For the full year, revenues reached $313.8 million, a 5% increase on a GAAP basis. Net income for Q4 2022 was $2.2 million compared to a net loss of $20.1 million in Q4 2021. The company anticipates 2023 revenue growth of 8.0% to 12%, with projected revenues between $331 million and $343 million. A CE mark for BioGlue was received, and confidence was noted for PMA approval for PerClot.

Artivion, Inc. (NYSE: AORT) announced its fourth-quarter and full-year 2022 financial results will be released on February 16, 2023, post-market. The Company will host a teleconference at 4:30 p.m. ET to discuss these results, followed by a Q&A session led by Pat Mackin, Chairman and CEO. Interested parties can listen live by dialing 201-689-8261 or access the webcast through the Artivion website. A replay will be available shortly after the call. Artivion specializes in medical devices for aortic diseases, offering products in over 100 countries.

Artivion, Inc. (NYSE: AORT) announced participation in two investor conferences on November 16 and November 17, 2022. The management team will present at the Stifel 2022 Healthcare Conference on November 16 at 9:10 a.m. ET, with a live webcast available on their website. Additionally, they will hold one-on-one meetings at the Canaccord Genuity MedTech Forum on November 17. Artivion specializes in medical devices for aortic diseases and operates in over 100 countries.

Artivion, Inc. (NYSE: AORT) reported third-quarter 2022 revenue of $76.8 million, marking a 6% increase on a GAAP basis compared to Q3 2021. Non-GAAP constant currency revenue grew by 11%. Notable growth came from On-X, with a 17% GAAP and 19% non-GAAP increase. Internationally, revenue rose by 25% in Asia Pacific and 22% in Latin America. However, the company faced a net loss of $13.7 million compared to a profit in the prior year. The revenue outlook for 2022 has been narrowed to $313.0-$316.0 million, projecting 9%-10% growth. The company also anticipates FDA approvals for key products by year-end.

Artivion, Inc. (NYSE: AORT) has announced that its third quarter 2022 financial results will be released on November 3, 2022, after market close. A teleconference will follow at 4:30 p.m. ET to discuss the results, led by Pat Mackin, the company's CEO. Investors can access the live webcast and replay on Artivion's website.

The company specializes in cardiac and vascular solutions for aortic diseases and sells products in over 100 countries worldwide.

Artivion, Inc. (NYSE: AORT) announced the appointment of Elizabeth A. Hoff to its Board of Directors, effective October 1, 2022. Hoff brings over 30 years of experience in the medical device industry, including senior roles in the aortic space. Her expertise will support Artivion's strategic growth initiatives and strengthen its market position in treating aortic diseases. Chairman and CEO Pat Mackin expressed enthusiasm for Hoff's inclusion, expecting her leadership to drive innovation and progress within the company.

Artivion, Inc. (AORT) announced the termination of the PROACT Xa clinical trial on September 23, 2022. The independent Data and Safety Monitoring Board recommended stopping the trial due to insufficient evidence supporting the non-inferiority of apixaban compared to warfarin for patients with On-X mechanical aortic valves. The trial, which began in April 2020, showed a higher incidence of blood clots and stroke in apixaban patients. Despite this setback, Artivion reiterated its commitment to double-digit growth and plans to redirect the previously allocated $10 million funding towards enhancing EBITDA and cash flow.

Artivion, Inc. (NYSE: AORT), a prominent company in cardiac and vascular surgery focused on aortic disease, announced it will present at the Deutsche Bank 30th Annual Leveraged Finance Conference on September 21, 2022, at 9:20 a.m. MST. The presentation will be available via a live webcast on the company's website, with an archived version accessible for 90 days. Artivion specializes in developing solutions for aortic diseases, marketing products in over 100 countries. For further details, visit www.artivion.com.